Bulk and Single-Cell Profiling of Breast Tumors Identifies TREM-1 as a Dominant Immune Suppressive Marker Associated With Poor Outcomes

SignaBlok > News

SignaBlok > News

Bulk and Single-Cell Profiling of Breast Tumors Identifies TREM-1 as a Dominant Immune Suppressive Marker Associated With Poor Outcomes

Pullikuth et al. Front Oncol. 2021

Commentary: Triggering Receptor Expressed on Myeloid Cells-1 Inhibitor Targeted to Endothelium Decreases Cell Activation

Sigalov AB. Front Immunol. 2020

Targeting Tumor-Associated Macrophages to Radiosensitize Glioblastoma in a Mouse Model

Mark DJ, Ruggieri M et al. Int J Radiat Oncol Biol Phys. 2019

SignaBlok presented data on preclinical antitumor activity of a first-in-class TREM-1 inhibitory peptide GF9 as monotherapy and in combo with chemotherapy or radiation at the 2019 AACR Annual Meeting

SignaBlok presented preclinical data supporting efficacy of ligand-independent TREM-1 inhibitor in ameliorating alcoholic liver disease at the Liver Meeting 2018: American Association for the Study of Liver Diseases (AASLD)

SignaBlok presented its concept of nature-inspired rational design of macrophage-targeted imaging and drug delivery system for detection and treatment of inflammation at the 2018 World Molecular Imaging Congress

SignaBlok awarded NIGMS / NIH SBIR Phase I grant to test novel TREM-1 therapy for treatment of sepsis

Novel TREM-1 Inhibitors Attenuate Tumor Growth and Prolong Survival in Experimental Pancreatic Cancer

Shen ZT and Sigalov AB. Mol Pharm. 2017

A novel ligand-independent peptide inhibitor of TREM-1 suppresses tumor growth in human lung cancer xenografts and prolongs survival of mice with lipopolysaccharide-induced septic shock

Sigalov AB. Int Immunopharmacol. 2014

SignaBlok awarded NEI / NIH SBIR Phase I grant to test new approach to prevention and treatment of neovascular retinal diseases